Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens [Hematologic Malignancy]

Conclusion Although all bortezomib-containing regimens produced good outcomes, VTD and VMP did not appear to offer an advantage over VD in transplantation-ineligible patients with myeloma treated in US community practice.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Geriatric Oncology, Translational Oncology Hematologic Malignancy Source Type: research